Warning: The NCBI web site requires JavaScript to function. more...
Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?
Menendez JA, Lupu R.
Breast Cancer Res. 2007;9(5):111.
Related citations
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.
Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM.
Nature. 2007 Jan 25;445(7126):437-41. Epub 2007 Jan 7.
ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
Anido J, Matar P, Albanell J, Guzmán M, Rojo F, Arribas J, Averbuch S, Baselga J.
Clin Cancer Res. 2003 Apr;9(4):1274-83.
An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R, Colomer R.
Int J Mol Med. 2007 Jul;20(1):3-10. Review.
Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
Sakai K, Yokote H, Murakami-Murofushi K, Tamura T, Saijo N, Nishio K.
Cancer Sci. 2007 Sep;98(9):1498-503. Epub 2007 Jul 11.
Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway.
Way TD, Kao MC, Lin JK.
J Biol Chem. 2004 Feb 6;279(6):4479-89. Epub 2003 Nov 5.
HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.
Kong A, Calleja V, Leboucher P, Harris A, Parker PJ, Larijani B.
PLoS One. 2008 Aug 6;3(8):e2881.
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Yao E, Zhou W, Lee-Hoeflich ST, Truong T, Haverty PM, Eastham-Anderson J, Lewin-Koh N, Gunter B, Belvin M, Murray LJ, Friedman LS, Sliwkowski MX, Hoeflich KP.
Clin Cancer Res. 2009 Jun 15;15(12):4147-56. Epub 2009 Jun 9.
A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM.
Cancer Res. 2008 Jul 15;68(14):5878-87.
Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
Lyne JC, Melhem MF, Finley GG, Wen D, Liu N, Deng DH, Salup R.
Cancer J Sci Am. 1997 Jan-Feb;3(1):21-30.
Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.
Albanell J, Codony J, Rovira A, Mellado B, Gascón P.
Adv Exp Med Biol. 2003;532:253-68. Review.
Biological and clinical significance of HER2 overexpression in breast cancer.
Kurebayashi J.
Breast Cancer. 2001;8(1):45-51. Review.
Role of HER2/HER3 co-receptor in breast carcinogenesis.
Way TD, Lin JK.
Future Oncol. 2005 Dec;1(6):841-9. Review.
Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.
Vazquez-Martin A, Colomer R, Brunet J, Lupu R, Menendez JA.
Cell Prolif. 2008 Feb;41(1):59-85.
Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.
Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A.
EMBO J. 1995 Sep 1;14(17):4267-75.
Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3.
Chen CH, Chernis GA, Hoang VQ, Landgraf R.
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9226-31. Epub 2003 Jul 21.
Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
Vazquez-Martin A, Oliveras-Ferraros C, Colomer R, Brunet J, Menendez JA.
Ann Oncol. 2008 Jun;19(6):1097-109. Epub 2008 Feb 17.
Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.
Gregory CW, Whang YE, McCall W, Fei X, Liu Y, Ponguta LA, French FS, Wilson EM, Earp HS 3rd.
Clin Cancer Res. 2005 Mar 1;11(5):1704-12.
Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3.
Chan SD, Antoniucci DM, Fok KS, Alajoki ML, Harkins RN, Thompson SA, Wada HG.
J Biol Chem. 1995 Sep 22;270(38):22608-13.
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.
Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, Arteaga CL.
Clin Cancer Res. 2007 Aug 15;13(16):4909-19.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on